Jump to content

2nd Annual Meeting of The Antibody Society of Japan

Kagoshima, Japan
December 1–3, 2023

Genedata Japan will be taking part in the 2nd Annual Meeting of The Antibody Society of Japan held in Kagoshima, Japan. 

Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, stratification of clinical trial subjects, and quality control of biologicals.

For more information about Genedata solutions, please contact info(at)genedata.com (English) or japan(at)genedata.com (Japanese).

Recommended Poster Presentations

[P-47] A Single Data Workflow Leveraging Middle-Down Sequencing to Validate Intact Mass Analysis Characterization of Therapeutic Antibodies
Tsubasa Ohashi, Ph.D., Scientific Account Manager, Genedata Expressionist, Genedata KK
Friday, December 1 | 4:50 – 5:40 pm

A faster and less complex alternative to characterizing antibodies by peptide mapping is middle-down intact mass analysis, which utilizes novel enzymes that cleave antibodies at a highly specific site above or below the hinge, resulting in well-defined fragments that are amenable to characterization by LC-MS/MS. 
We present a fully automated data processing workflow that enables fast and efficient middle-down protein sequencing and simultaneous intact mass analysis of protein biotherapeutics. The sequencing results can be used to validate the intact mass analysis and confirm the presence of post-translationally modified and clipped species. After enzymatic digestion with IdeS protease, subunit samples were separated by LC-MS/MS analysis. MS data was processed and analyzed using Genedata Expressionist software (Genedata AG, Basel). 
In summary, we have developed a dedicated, automated MS data processing workflow for simultaneous middle-down sequencing and identification of modified and clipped biopharmaceutical subunit fragments. 

[P-107] Improving Efficiency in Discovery and Development of Bispecifics and ADCs
Meripet Yamanaka, Ph.D., Scientific Account Manager, Genedata Biologics/Bioprocess, Genedata KK
Saturday, December 2 | 5:30 – 6:20 pm

Research and development (R&D) workflows for large-molecule therapeutics require comprehensive documentation of protocols, process parameters, as well as experimental entities including vectors, cell lines, expression and purification batches, and samples. We present a new registration platform, developed together with major biopharma, which enables registration and tracking of biologics and the workflows used in their discovery and development. The platform can handle complex pools and mixtures, as well as diverse modalities including therapeutic proteins, viruses, mRNAs, and vaccines. Here, we present concrete registration applications for highly engineered molecules such as bispecific antibodies and antibody-drug conjugates (ADCs). Designed to interface and integrate with existing IT infrastructures, the platform can be configured to support corporate-specific variants of registration business logic such as proprietary molecule formats, uniqueness checks, or tailor-made naming conventions.
In Summary, the platform allows sharing of molecule and sample ID spaces across both large- and small-molecule applications, substantially increasing digitalization efficiency and quality along the full R&D process.